Cannabinoid Formula for ADHD, Anxiety, and Neurological Disorders Arrives in Brazil in August

A new cannabinoid-based formulation has just arrived in Brazil, focusing on the treatment of disorders such as ADHD, anxiety, sleep disturbances, and inflammation affecting the nervous system. Developed by the company Alma Lab, the composition combines four non-psychoactive phytocannabinoids — CBD, CBG, CBC, and CBDV — and proposes a therapeutic approach aligned with recent research on the endocannabinoid system.

Based on the latest research on the benefits of non-psychoactive cannabinoids, the new formula is indicated for adults over 18 years old, especially those dealing with attention disorders, hyperactivity, and anxiety, as well as gynecological and dermatological diseases due to its antibacterial and antifungal properties. The product is also aimed at athletes and sportspeople facing muscle pain, sleep disturbances, and systemic inflammation.

According to Alma Lab, the main differentiator lies in the synergistic action of the compounds — the so-called entourage effect — which enhances the clinical efficacy of the formulation. “This is an integrated approach that acts on multiple molecular targets related to anxiety, neuroinflammation, and mood regulation, without the psychoactive effects of THC,” emphasizes the company's scientific team.

The composition acts on the CB1, CB2, TRPV1, TRPA1, PPAR-gamma, and alpha-2 adrenergic receptors, providing anxiolytic, neuroprotective, anti-inflammatory, and regenerative effects. The proposal is to cater to both patients with neurodevelopmental disorders and adults diagnosed late with ADHD — a disorder that affects about 7% of the Brazilian population and often manifests without diagnosis until adulthood.